Abstract
Signal transduction pathways regulate the proliferation, differentiation, migration, and survival of melanocytes. These signaling pathways are dysregulated during the transformation of melanocytes, often due to somatic mutation of genes within the pathway. One major signaling pathway that highlights this paradigm is the mitogen-activated protein (MAP) kinase pathway. Growth factor signaling via the MAP kinase pathway is required for melanocyte proliferation and survival. MAP kinase signaling is activated in the majority of melanomas through somatic mutations in NRAS, BRAF, and MEK1/2. Regulation of proliferation and survival is also controlled by phosphatidyl-inositol 3′-kinase (PI3K) signaling. PI3K is a major regulator of melanocyte biology and is commonly activated through the mutation/loss of expression of negative not pathway regulators such as PTEN. Alterations in cyclin-dependent kinase signaling are also frequent in melanoma and promote aberrant cell cycle progression. Other pathways such as Gαq, Wnt (canonical and noncanonical), Hippo, Notch, and signaling downstream of Rho family GTPases also play important roles in the aforementioned biological processes, and in some cases are altered in selective subsets of melanoma. The high mutation burden within genes in signaling pathways, the important role of these pathways in melanocytic neoplasms, and the knowledge that melanomas adapt their signaling mechanisms in response to targeted inhibitors make it essential to have a thorough understanding of the key signaling pathways in melanocytes and melanomas.
Similar content being viewed by others
References
Ackermann J et al (2005) Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. Cancer Res 65(10):4005–4011
Anastas JN et al (2014) WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors. J Clin Invest 124(7):2877–2890
Arozarena I et al (2011a) Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. Cancer Cell 19(1):45–57
Arozarena I et al (2011b) In melanoma, beta-catenin is a suppressor of invasion. Oncogene 30(45):4531–4543
Bachmann IM et al (2005) Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clin Cancer Res 11(24 Pt 1):8606–8614
Baenke F et al (2016) Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells. Mol Oncol 10(1):73–84
Balmanno K, Cook SJ (2009) Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ 16(3):368–377
Bedogni B (2014) Notch signaling in melanoma: interacting pathways and stromal influences that enhance Notch targeting. Pigment Cell Melanoma Res 27(2):162–168
Bedogni B et al (2008) Notch1 is an effector of Akt and hypoxia in melanoma development. J Clin Invest 118(11):3660–3670
Berger MF et al (2012) Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 485(7399):502–506
Bhatt KV et al (2005) Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling. Oncogene 12(24):3459–3471
Bhatt KV et al (2007) Mutant B-RAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27(Kip1) in human melanoma cells. Oncogene 26(7):1056–1066
Biechele TL et al (2012) Wnt/beta-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma. Sci Signal 5(206):ra3
Bigas A, Guiu J, Gama-Norton L (2013) Notch and Wnt signaling in the emergence of hematopoietic stem cells. Blood Cells Mol Dis 51(4):264–270
Boisvert-Adamo K, Aplin AE (2008) Mutant B-RAF mediates resistance to anoikis via Bad and Bim. Oncogene 27(23):3301–3312
Borggrefe T et al (2016) The Notch intracellular domain integrates signals from Wnt, Hedgehog, TGFbeta/BMP and hypoxia pathways. Biochim Biophys Acta 1863(2):303–313
Botton T et al (2013) Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy. Pigment Cell Melanoma Res 26(6):845–851
Brady SC et al (2009) Sprouty2 association with B-Raf is regulated by phosphorylation and kinase conformation. Cancer Res 69(17):6773–6781
Brummer T et al (2003) Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf. Oncogene 22(55):8823–8834
Busca R et al (2000) Ras mediates the cAMP-dependent activation of extracellular signal-regulated kinases (ERKs) in melanocytes. EMBO J 19(12):2900–2910
Cartlidge RA et al (2008) Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival. Pigment Cell Melanoma Res 21(5):534–544
Carvajal RD et al (2014) Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA 311(23):2397–2405
Chen X et al (2014) Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations. Oncogene 33(39):4724–4734
Chen X et al (2017) RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma. Cancer Cell 31(5):685–696 e6
Chien AJ et al (2009) Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc Natl Acad Sci U S A 106(4):1193–1198
Chien AJ et al (2014) Targeted BRAF inhibition impacts survival in melanoma patients with high levels of Wnt/beta-catenin signaling. PLoS One 9(4):e94748
Chin L et al (1997) Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev 11(21):2822–2834
Conde-Perez A et al (2015) A caveolin-dependent and PI3K/AKT-independent role of PTEN in beta-catenin transcriptional activity. Nat Commun 6:8093
Curtin JA et al (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353(20):2135–2147
Damsky WE et al (2011) β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell 20(6):741–754
Dankort D et al (2009) Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41(5):544–552
Davies H et al (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949–954
Davies MA et al (2008) A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer 99(8):1265–1268
Delmas V et al (2007) Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev 21(22):2923–2935
Deuker MM et al (2015) PI3′-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma. Cancer Discov 5(2):143–153
Dissanayake SK et al (2008) Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation. Cancer Res 68(24):10205–10214
Dumaz N et al (2006) In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res 66(19):9483–9491
Eskandarpour M et al (2005) Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells. Int J Cancer 115(1):65–73
Feng X et al (2014) Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell 25(6):831–845
Ferguson B et al (2015) Melanoma susceptibility as a complex trait: genetic variation controls all stages of tumor progression. Oncogene 34(22):2879–2886
Gewinner C et al (2009) Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell 16(2):115–125
Gray-Schopfer VC et al (2006) Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br J Cancer 95(4):496–505
Ha L et al (2007) ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence. Proc Natl Acad Sci U S A 104(26):10968–10973
Harbour JW et al (2010) Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330(6009):1410–1413
Hoek KS et al (2006) Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res 19(4):290–302
Horrigan SK et al (2017) Replication study: melanoma genome sequencing reveals frequent PREX2 mutations. Elife 6:e21634
Huang JL, Urtatiz O, Van Raamsdonk CD (2015) Oncogenic G protein GNAQ induces uveal melanoma and intravasation in mice. Cancer Res 75(16):3384–3397
Hutchinson KE et al (2013) BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. Clin Cancer Res 19(24):6696–6702
Inoue-Narita T et al (2008) Pten deficiency in melanocytes results in resistance to hair graying and susceptibility to carcinogen-induced melanomagenesis. Cancer Res 68(14):5760–5768
Jakob JA et al (2012) NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118(16):4014–4023
Joseph EW et al (2010) The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A 107(33):14903–14908
Kannan K et al (2003) Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model. Proc Natl Acad Sci U S A 100(3):1221–1225
Kaur A et al (2016) sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature 532:250
Klein RM et al (2008) B-RAF regulation of Rnd3 participates in actin cytoskeletal and focal adhesion organization. Mol Biol Cell 19(2):498–508
Koelsche C et al (2015) Melanotic tumors of the nervous system are characterized by distinct mutational, chromosomal and epigenomic profiles. Brain Pathol 25(2):202–208
Krauthammer M et al (2015) Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nat Genet 47(9):996–1002
Kwong LN et al (2012) Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med 18:1503
Lamar JM et al (2012) The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci U S A 109(37):E2441–E2450
Larribere L et al (2004) PI3K mediates protection against TRAIL-induced apoptosis in primary human melanocytes. Cell Death Differ 11(10):1084–1091
Larue L et al (2009) Bypassing melanocyte senescence by beta-catenin: a novel way to promote melanoma. Pathol Biol (Paris) 57:543
Lee EK et al (2013) The FBXO4 tumor suppressor functions as a barrier to BRAFV600E-dependent metastatic melanoma. Mol Cell Biol 33(22):4422–4433
Li Chew C et al (2015) In vivo role of INPP4B in tumor and metastasis suppression through regulation of PI3K-AKT signaling at endosomes. Cancer Discov 5(7):740–751
Li A et al (2012) Activated mutant NRas(Q61K) drives aberrant melanocyte signaling, survival, and invasiveness via a Rac1-dependent mechanism. J Invest Dermatol 132(11):2610–2621
Lindsay CR et al (2011) P-Rex1 is required for efficient melanoblast migration and melanoma metastasis. Nat Commun 2:555
Lindsay CR et al (2015) A Rac1-independent role for P-Rex1 in melanoblasts. J Invest Dermatol 135(1):314–318
Lito P et al (2012) Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 22(5):668–682
Liu H et al (2015) Mutant GNAQ promotes cell viability and migration of uveal melanoma cells through the activation of Notch signaling. Oncol Rep 34(1):295–301
Madhunapantula SV, Sharma A, Robertson GP (2007) PRAS40 deregulates apoptosis in malignant melanoma. Cancer Res 67(8):3626–3636
Marsh Durban V et al (2013) Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma. J Clin Invest 123(12):5104–5118
McKay MM, Freeman AK, Morrison DK (2011) Complexity in KSR function revealed by Raf inhibitor and KSR structure studies. Small GTPases 2(5):276–281
Mense SM et al (2015) PTEN inhibits PREX2-catalyzed activation of RAC1 to restrain tumor cell invasion. Sci Signal 8(370):ra32
Michaloglou C et al (2005) BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436(7051):720–724
Monahan KB et al (2010) Somatic p16(INK4a) loss accelerates melanomagenesis. Oncogene 29(43):5809–5817
Nallet-Staub F et al (2014) Pro-invasive activity of the Hippo pathway effectors YAP and TAZ in cutaneous melanoma. J Invest Dermatol 134(1):123–132
Nemeth MJ et al (2007) Wnt5a inhibits canonical Wnt signaling in hematopoietic stem cells and enhances repopulation. Proc Natl Acad Sci U S A 104(39):15436–15441
Nikolaev SI et al (2012) Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet 44(2):133–139
O’Connell MP, Weeraratna AT (2009) Hear the Wnt Ror: how melanoma cells adjust to changes in Wnt. Pigment Cell Melanoma Res 22:724
O’Connell MP et al (2013) Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov 3(12):1378–1393
Paraiso KHT et al (2011) PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 71(7):2750–2760
Pollock PM et al (2003) High frequency of BRAF mutations in nevi. Nat Genet 33(1):19–20
Pratilas CA et al (2009) V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A 106(11):4519–4524
Ranganathan P, Weaver KL, Capobianco AJ (2011) Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer 11(5):338–351
Robbins PF et al (1996) A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 183(3):1185–1192
Rushworth LK et al (2006) Regulation and role of Raf-1/B-Raf heterodimerization. Mol Cell Biol 26(6):2262–2272
Sanchez IM, Aplin AE (2014) Hippo: hungry, hungry for melanoma invasion. J Invest Dermatol 134(1):14–16
Sauter ER et al (2002) Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res 62(11):3200–3206
Scortegagna M et al (2014) Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf::Pten melanoma. Oncogene 33:4330–4339
Scortegagna M et al (2015) PDK1 and SGK3 contribute to the growth of BRAF-mutant melanomas and are potential therapeutic targets. Cancer Res 75(7):1399–1412
Scott G, Cassidy L, Busacco A (1997) Fibronectin suppresses apoptosis in normal human melanocytes through an integrin-dependent mechanism. J Invest Dermatol 108(2):147–153
Shain AH et al (2015) Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. Nat Genet 47(10):1194–1199
Shao Y, Aplin AE (2012) ERK2 phosphorylation of serine 77 regulates Bmf pro-apoptotic activity. Cell Death Dis 3:e253
Shao H et al (2011) Activation of Notch1 signaling in stromal fibroblasts inhibits melanoma growth by upregulating WISP-1. Oncogene 30(42):4316–4326
Shin MK et al (1999) The temporal requirement for endothelin receptor-B signalling during neural crest development. Nature 402(6761):496–501
Solit DB et al (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439(7074):358–362
Sotillo R et al (2001) Invasive melanoma in Cdk4-targeted mice. Proc Natl Acad Sci U S A 98(23):13312–13317
Spranger S, Bao R, Gajewski TF (2015) Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 523(7559):231–235
Stahl JM et al (2004) Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 64(19):7002–7010
TCGA (2015) Genomic classification of cutaneous melanoma. Cell 161(7):1681–1696
Van Brocklin MW et al (2009) Mitogen-activated protein kinase inhibition induces translocation of Bmf to promote apoptosis in melanoma. Cancer Res 69(5):1985–1994
Van Raamsdonk CD et al (2009) Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457(7229):599–602
Van Raamsdonk CD et al (2010) Mutations in GNA11 in uveal melanoma. N Engl J Med 363(23):2191–2199
Wan PT et al (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116(6):855–867
Watson IR et al (2014) The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF. Cancer Res 74(17):4845–4852
Weber CK et al (2001) Active ras induces heterodimerization of cRaf and BRaf. Cancer Res 61(9):3595–3598
Webster MR, Kugel CH 3rd, Weeraratna AT (2015a) The Wnts of change: how Wnts regulate phenotype switching in melanoma. Biochim Biophys Acta 1856(2):244–251
Webster MR et al (2015b) Wnt5A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cells. Pigment Cell Melanoma Res 28(2):184–195
Weeraratna AT et al (2002) Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 1(3):279–288
Weiss MB et al (2012) TWIST1 is an ERK1/2 effector that promotes invasion and regulates MMP-1 expression in human melanoma cells. Cancer Res 72(24):6382–6392
Welch HC (2015) Regulation and function of P-Rex family Rac-GEFs. Small GTPases 6(2):49–70
Wolfel T et al (1995) A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269(5228):1281–1284
Xing F et al (2012) Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene 31(4):446–457
Yeh I et al (2017) Combined activation of MAP kinase pathway and β-catenin signaling cause deep penetrating nevi. Nat Com 8(1):644. https://doi.org/10.1038/s41467-017-00758-3
Zhang G et al (2016) Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. J Clin Invest 126(5):1834–1856
Zheng B et al (2009) Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell 33(2):237–247
Acknowledgments
The Aplin Laboratory is supported by the NIH under award numbers: CA196278, CA160495 and CA182635, and by the Melanoma Research Alliance. The Weeraratna Laboratory is supported by NIH grants: CA174746, CA114046, CA207935, CA174523 and grants from the Melanoma Research Foundation and the Melanoma Research Alliance/L’Oreal.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media LLC
About this entry
Cite this entry
Aplin, A.E., Weeraratna, A.T. (2018). Key Signaling Pathways in Normal and Neoplastic Melanocytes. In: Fisher, D., Bastian, B. (eds) Melanoma. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-7322-0_26-1
Download citation
DOI: https://doi.org/10.1007/978-1-4614-7322-0_26-1
Received:
Accepted:
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-7322-0
Online ISBN: 978-1-4614-7322-0
eBook Packages: Springer Reference MedicineReference Module Medicine